As Celgene Corp (CELG) Stock Price Declined, Eulav Asset Management Boosted by $3.02 Million Its Stake

April 16, 2018 - By Winifred Garcia

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.83 in Q4 2017. Its down 0.34, from 1.17 in 2017Q3. It dived, as 156 investors sold CELG shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. 406,177 were reported by Victory Management Inc. Bridgewater Assoc Limited Partnership has 290,776 shares. Thompson Siegel And Walmsley Lc holds 2,669 shares or 0% of its portfolio. Highbridge Mngmt Limited Liability Corp has invested 0.23% of its portfolio in Celgene Corporation (NASDAQ:CELG). Pensionfund Dsm Netherlands reported 43,100 shares. The United Kingdom-based Glg Prns Lp has invested 0.05% in Celgene Corporation (NASDAQ:CELG). Great Lakes Limited Liability accumulated 3,642 shares or 0.01% of the stock. Northrock Ptnrs Limited Liability Co reported 8,410 shares. Louisiana State Employees Retirement Sys invested 0.23% of its portfolio in Celgene Corporation (NASDAQ:CELG). Secor Capital Advisors LP has 0.12% invested in Celgene Corporation (NASDAQ:CELG). 11,925 are held by Van Cleef Asset Managementinc. Raab And Moskowitz Asset Mngmt Limited Liability invested in 0.32% or 6,267 shares. Btg Pactual Global Asset Mngmt Limited has invested 0.4% in Celgene Corporation (NASDAQ:CELG). Jane Street Gru Limited Liability holds 0.03% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 94,200 shares. Fagan Associates Incorporated invested in 30,480 shares.

Since February 8, 2018, it had 1 insider purchase, and 3 insider sales for $3.58 million activity. MARIO ERNEST had sold 13,370 shares worth $1.26M on Friday, February 23. KAPLAN GILLA also sold $1.77 million worth of Celgene Corporation (NASDAQ:CELG) shares. Shares for $299,594 were bought by Alles Mark J on Thursday, February 8.

Eulav Asset Management increased its stake in Celgene Corp (CELG) by 16.29% based on its latest 2017Q4 regulatory filing with the SEC. Eulav Asset Management bought 29,000 shares as the company’s stock declined 19.30% with the market. The institutional investor held 207,000 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $21.60 million, up from 178,000 at the end of the previous reported quarter. Eulav Asset Management who had been investing in Celgene Corp for a number of months, seems to be bullish on the $68.39B market cap company. The stock increased 1.70% or $1.52 during the last trading session, reaching $90.92. About 1.85 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since April 16, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Eulav Asset Management, which manages about $2.35B and $2.12 billion US Long portfolio, decreased its stake in Allergan Plc by 20,000 shares to 4,272 shares, valued at $699,000 in 2017Q4, according to the filing. It also reduced its holding in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by 27,000 shares in the quarter, leaving it with 69,000 shares, and cut its stake in Tjx Cos Inc New (NYSE:TJX).

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 28 analysts covering Celgene (NASDAQ:CELG), 15 have Buy rating, 1 Sell and 12 Hold. Therefore 54% are positive. Celgene had 61 analyst reports since October 17, 2017 according to SRatingsIntel. JMP Securities downgraded Celgene Corporation (NASDAQ:CELG) on Friday, October 27 to “Hold” rating. The rating was maintained by SunTrust on Friday, October 27 with “Buy”. Morgan Stanley maintained Celgene Corporation (NASDAQ:CELG) rating on Monday, October 23. Morgan Stanley has “Underweight” rating and $115 target. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Friday, October 20 by Cowen & Co. The rating was maintained by Stifel Nicolaus on Friday, October 20 with “Buy”. The firm has “Buy” rating by Mizuho given on Monday, February 5. The stock of Celgene Corporation (NASDAQ:CELG) earned “Overweight” rating by JP Morgan on Wednesday, March 21. BMO Capital Markets maintained Celgene Corporation (NASDAQ:CELG) on Friday, October 27 with “Outperform” rating. The stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by BMO Capital Markets on Friday, November 17. The stock of Celgene Corporation (NASDAQ:CELG) has “Overweight” rating given on Friday, December 8 by Atlantic Securities.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: